SCHEMBL6901210

SCHEMBL6901210

N[C@@H]1C[C@@H]1c1c(F)cccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 17/20 0.59
KDM1B Q8NB78 3/20 0.59
HTR2C P28335 2/20 0.57
HTR2B P41595 1/20 0.57
MAOA P21397 6/20 0.52
MAOB P27338 6/20 0.52
CYP2C19 P33261 4/20 0.44
CYP2B6 P20813 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 2/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
CYP2A6 P11509 1/20 0.44
SLC6A2 P23975 1/20 0.44
ADRA1A P35348 1/20 0.44
DRD3 P35462 1/20 0.44
SLC6A3 Q01959 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6905308 1.00 KDM1A (0.59) KDM1AKDM1BHTR2CHTR2BMAOA
SCHEMBL16212239 0.82 HTR2C (0.48) KDM1AKDM1BHTR2CHTR2BMAOA
SCHEMBL14774665 0.76 KDM1A (0.70) KDM1AKDM1BHTR2CHTR2BMAOA
SCHEMBL15541116 0.74 KDM1A (1.00) KDM1AKDM1BHTR2CHTR2BMAOA
SCHEMBL15541761 0.74 KDM1A (1.00) KDM1AKDM1BHTR2CHTR2BMAOA
SCHEMBL13742189 0.74 HTR2C (0.96) HTR2CHTR2BMAOBSLC6A2SLC6A3
SCHEMBL22181251 0.74 KDM1A (1.00) KDM1AKDM1BHTR2CHTR2BMAOA
Hydrochloric Acid SCHEMBL16987728 0.73 KDM1A (0.96) KDM1AKDM1BHTR2CHTR2BMAOA
Hydrochloric Acid SCHEMBL4140621 0.73 HTR2C (1.00) HTR2CHTR2BMAOBSLC6A2SLC6A3
Hydrochloric Acid SCHEMBL4140619 0.73 HTR2C (1.00) HTR2CHTR2BMAOBSLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116418-A1 Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB (SE) 2004-06-17 US disclosed
US-20020132794-A1 Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB 2002-09-19 US disclosed
US-6376492-B1 GUANIDINE DERIVATIVES MEDIVIR AB (SE) 2002-04-23 US disclosed
US-5849769-A N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection MEDIVIR AB (SE) 1998-12-15 US disclosed
EP-0706514-B1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1998-11-18 EP disclosed
EP-0706514-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1996-04-17 EP disclosed
WO-1995006034-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1995-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132794-A1 Compounds and methods for inhibition of HIV and related viruses POLRMT, POLM, POLR1E KDM1A 1796/4885KDM1B 1346/4885HTR2C 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.